Should I buy, hold, or sell XFOR stock right now?

X4 Pharmaceuticals Inc. (XFOR) currently earns a Roarable Rating of E (Strong Sell — SELL) with 29/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is XFOR's 12-month price target and RQD AI Jury consensus?

XFOR's 12-month base price target is $2.91 (range $2.27 to $5.07), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / XFOR

ALEC (33) KYTX (35) AGEN (29) IRLA (34) ⌘ Pro Terminal →

X4 Pharmaceuticals Inc. (XFOR) — RQD Stock Rating Cockpit

$3.35 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.34

X4 Pharmaceuticals Inc. (XFOR) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $332.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XFOR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XFOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.35 (0.00% 1D, market cap $332.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XFOR ranks #830 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XFOR compare to ALEC and KYTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), XFOR carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 83.6%, and ROIC of -35.0%. By comparison, ALEC (Alector Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $327.6M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $350.7M). Among the 5-stock peer group, XFOR leads on earnings multiple (N/A) while XFOR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XFOR?

▼

Per XFOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501697), X4 Pharmaceuticals Inc. generated $35.1M in revenue (+1273.2% YoY), -$79.2M in net income, and -$85.6M in free cash flow against $290.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.34 (-0.19%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XFOR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY XFOR SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (24% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 60.1 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.60+16.2% Next Q

Q2 (-2Q)

Grade E$3.02+7.6% Next Q

Q3 (-1Q)

Grade E$3.25+3.1% Next Q

Current

Grade E$3.35-9.8% Hist 90D α

Trajectory: E (21) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XFOR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XFOR currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.52) forces dealer call-delta covering toward $5.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XFOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XFOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

60.130 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE38% OF RANGE

L: $2$3.35H: $5

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on XFOR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 83.6% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like XFOR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XFOR)

✓Walkthrough of XFOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XFOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.43%📐 HORIZONTAL RANGE

2026-11-03O $3.36H $3.36L $3.35C $3.35VOL 706.3K

RES: $5.04SUP: $2.16SMA50: $3.30SMA200: $3.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XFOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XFOR Butterfly Map → + Track XFOR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +1273.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XFOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XFOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XFOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XFOR)

Health Care Rank #830 of 1015 ⚔️ ALEC vs XFOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XFOR vs. ALEC, KYTX, AGEN, IRLA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, X4 Pharmaceuticals Inc. (XFOR) ranks #830 by composite RQD confidence (29/100, grade E) and #504 by equity capitalization ($332.1M). Within this direct 5-issuer industry benchmark cohort, XFOR leads on earnings valuation at N/A trailing P/E, while XFOR leads on capital efficiency and profitability with -35.0% ROIC and 83.6% gross margin. KYTX currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with XFOR at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XFOR ACTIVE X4 Pharmaceuticals Inc.	E	29/100	—	83.6%	-35.0%	0.00%	$332.1M	Benchmark Subject
ALEC Alector Inc.	E	33/100	—	—	-35.0%	-2.71%	$327.6M	/alec-vs-xfor →
KYTX Kyverna Therapeutics Inc.	D-	35/100	—	—	-35.0%	-7.94%	$350.7M	/kytx-vs-xfor →
AGEN Agenus Inc.	E	29/100	—	96.0%	-35.0%	-4.53%	$308.9M	/agen-vs-xfor →
IRLA IRulya Therapeutics Inc.	E	34/100	—	—	-35.0%	+1.82%	$357.2M	/irla-vs-xfor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501697 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported GAAP revenue of $35.1M (+1273.2% vs. FY2024 revenue of $2.6M , and -88.3% cumulative change since FY2023) , GAAP net income of -$79.2M, operating cash flow of -$85.6M, and free cash flow of -$85.6M (+34.8% YoY). On the balance sheet, XFOR closed FY2025 with $290.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.1M	-$79.2M	-$85.6M	-$85.6M	$290.5M	—
FY2024 (FY)	2024-12-31	$2.6M	-$37.5M	-$130.9M	-$131.2M	$146.4M	—
FY2023 (FY)	2023-12-31	$301.1M	-$101.2M	-$96.5M	-$96.5M	—	—

3. XFOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XFOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does XFOR compare to ALEC and KYTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for XFOR?

Where is XFOR trading relative to its 50-day, 200-day, and 52-week technical levels?

XFOR last traded at $3.35 (0.00% on volume of 521,970 shares), positioning the stock +1.52% above its 50-day simple moving average ($3.30) and -11.84% below its 200-day simple moving average ($3.80). Across its 52-week range of $2.43 to $4.83, XFOR sits at the 38.3% percentile with a 14-day RSI of 60.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.93 to $3.77).

Direct Sub-Reports: XFOR RQD Cockpit XFOR 12M Forecast XFOR Earnings & Move XFOR Dividends & DRIP XFOR Insiders & 13F XFOR Whale Options XFOR Profit Sankey XFOR News & Why

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

XFOR — X4 Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

X4 Pharmaceuticals Inc. (XFOR) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.35 (0.00% 1D, market capitalization $332.1M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 83.6%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

X4 Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company's product sales, customer base, and revenue model are not described in the supplied source data. The SEC financials show reported revenue of $35.1M in FY 2025, up from $2.6M in FY 2024 and — in FY 2023. Per the market data, gross margin is 83.6%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), X4 Pharmaceuticals Inc. (XFOR) reported $35.1M in annual revenue (up from $2.6M in FY2024, +1273.2% YoY) and -$79.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($301.1M revenue, -$101.2M net income) through FY2025, XFOR scaled operating cash flow to -$85.6M and free cash flow to -$85.6M, backed by $290.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.43 – $4.83 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, therefore, cannot be mapped from the supplied data. Sector correlation is limited to the profile classification (Health Care; Biotechnology: Biological Products) and the Roarable RQD macro regime pillar, which records beta of 1.0 and a sector sensitivity score within 7 of 20. A prospective investor should watch whether the financing and the planned Q1 2027 study alter the cash trajectory, since the supplied data contains no second-order supplier or customer linkages to test that effect.

Key Question #1: Can XFOR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $35.1M and free cash flow of -$85.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is XFOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XFOR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for X4 Pharmaceuticals Inc. (XFOR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XFOR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

X4 Pharmaceuticals Enters Up to $150 Million Term Loan Facility

Yahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

X4 Pharmaceuticals(XFOR) Stock Options Chain | Quotes & News

Moomoo report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

X4 Pharmaceuticals, Inc. Estimates – NASDAQ:XFOR

TradingView report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

Yahoo Finance report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A second mavorixafor study is planned for Q1 2027 at X4 Pharmaceuticals (XFOR).

Stock Titan report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

X4 Pharmaceuticals stock: Wells Fargo keeps Buy rating for X4 Pharmaceuticals stock at USD 11.00

ad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

X4 Pharmaceuticals stock: Chairman Adam Craig buys 4,600 shares of X4 Pharmaceuticals stock

ad-hoc-news.de report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TipRanks • 1d ago

X4 Pharmaceuticals Highlights Strategic Focus on Rare Hematology

TipRanks report covering X4 Pharmaceuticals Inc. (XFOR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XFOR Bull vs. Bear Conversation Board — What's Your Call at $3.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XFOR 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $4.29 (+28.1%)

📌 Pinned Debate

FY 2025 revenue reached $35.1M, up from $2.6M in FY 2024, and reported cash rose to $217.0M.

Picked up a starter position in XFOR in my $100K Virtual Cash book at $3.35. FY 2025 revenue reached $35.1M, up from $2.6M in FY 2024, and reported cash rose to $217.0M.. Trading inside a $2.43–$4.83 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — XFOR's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.58 (-23.0%)

Spot @ $3.35

Operating margin of -60% and ROIC of -35% sit alongside an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9.

Careful chasing XFOR at $3.35. Operating margin of -60% and ROIC of -35% sit alongside an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9.. Gross margin is 83.6%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.58 on multiple compression.